Summary. The insulin-antagonistic effect of adrenaline was studied in seven healthy subjects with the euglycaemic clamp technique using two insulin infusion rates (40 and 1200 mU. (m 2)-l min-1). The adrenergic receptor mediating the adrenaline effect was characterized by concomitant infusion of propranolol (j31 +fl2-antagonist) or metoprolol (ill-antagonist). Each subject was studied four times (placebo, adrenaline, adrenaline + propranolol, adrenaline + metoprolol). Glucose turnover was measured with D(3-3H)-glucose. Similar plasma insulin levels were reached in all studies with the two insulin infusion rates (mean; placebo 51 _+ 3 and 7421 +_ 337 mU/l respectively). Glucose production was completely inhibited by the low insulin level during placebo infusion. Adrenaline antagonized this effect so that a significant glucose production was seen at the low but not at the high insulin level. Proprano1ol, but not metoprolol, reversed this insulin-antagonistic effeet of adrenaline. Glucose utilization increased from 2.53 _+ 0.17 to 7.28 _+ 0.88 mg. kg -1. rain -~ during placebo when the insulin levels were increased from 4 + 0.3 to 51 _+ 3 mU/1. Increasing the insulin levels 150-fold to ~7500 mU/1 only doubled the glucose utilization (14.68 + 1.14 mg. kg -1. min-l). Adrenaline induced a pronounced inhibition of glucose utilization at both insulin levels (78% and 37% inhibition respectively). Propranolol, but not metoprolol, prevented this effect of adrenaline. Thus, physiological adrenaline levels exert a pronounced insulin-antagonistic effect which is mediated by fl2-receptor stimulation. The inhibitory effect on glucose uptake is maintained even at high insulin levels when hepatic glucose production is completely abolished.
Hyperglycaemia is a frequent finding during various stressful conditions. The importance of catecholamines for the perturbed glucose tolerance is underlined by the ability of these hormones to impair insulin release [1, 2] as well as to exert an effect on glucose turnover [2, 3] . Further clinical support for the importance of catecholamines is offered by the high prevalence of diabetes in patients with a phaeochromocytoma [4] . The glucose levels in this condition are also normalized following the removal of the tumour [4] . Furthermore, the metabolic control deteriorates in diabetic patients during various stressful conditions such as infections, stroke and myocardial infarction [5] . The effect of catecholamines in raising the glucose levels is of major importance for the counter-regulatory action of these hormones during hypoglycaemia, particularly when the glucagon release is impaired [6] ; this occurs frequently in Type I (insulin-dependent) diabetes [7, 8] .
The insulin-antagonistic effect of catecholamines is due to both an increased hepatic glucose production and to a decreased peripheral utilization [3, 9] . Although these effects are well-documented, little is known about the normal interaction between insulin and catecholamines in man as well as the type of adrenergic receptor mediating the insulin-antagonistic effect. Furthermore, it is not known if the catecholamines are equally effective in antagonizing the insulin action on hepatic glucose production and on peripheral glucose uptake.
The inhibitory effect of adrenaline on glucose utilization seems to be mediated by fl-adrenoceptor stimulation [9] . Experimental studies with isolated fat cells in vitro have also shown that catecholamines, via r-stimulation, exert a marked inhibitory effect on the insulinstimulated glucose transport [10, 11] . This effect seems to be due to both an inhibition of the insulin-induced translocation of the glucose transporters from the intracellular pool to the plasma membrane and to a reduced inherent activity of the glucose transporters [10, 11] . In addition, recent studies have shown that catecholamines, via r-stimulation, are capable of inducing a rapid reduction in insulin binding [12] [13] [14] . Thus, these studies have shown that catecholamines can rapidly (t½~2min) induce a marked resistance to insulin through both receptor-and postreceptor-mediated perturbations [10] [11] [12] [13] [14] . The aim of the present study was to evaluate the insulin-antagonistic effect of adrenaline in normal man on both glucose production and utilization at different insulin level. To characterize the type of adrenergic receptor mediating these effects, experiments were performed with the r-receptor blocking agents propranolol (ill + flz-antagonist) and metoprolol (/71-antagonist).
Subjects and methods

Subjects
Seven healthy male subjects, aged 23-30 years, were studied. All subjects were of normal weight, had normal fasting glucose levels, and lacked a family history of diabetes. None of the subjects took any regular medication. The characteristics of the subjects are shown in Table 1 . Informed consent was obtained from all subjects and the study was approved by the Ethical Committee of the University of Gothenburg, Sweden.
Infusions
All infusions were made through a Drum-Cartridge catheter placed in a cubital vein. Blood samples were collected from a catheter placed in the contralateral cubital vein. The arm was warmed with an electric pad to arterialize the venous blood. Insulin (Actrapid, Novo, Copenhagen, Denmark) was infused at a concentration of 0.6 IU/ml in isotonic saline with 4 mg/ml albumin added to prevent glass adhesion. Glucose (300mg/ml) containing potassium chloride (40retool per 500 ml) was infused at variable rates in the same catheter as the insulin. This procedure prevented the development of hypokalaemia in the subjects. To evaluate the effect of adrenaline on glucose metabolism and to characterize the type of adrenergic receptor mediating the adrenaline response, the subjects were infused in a randomized order with adrenaline (Adrenaline, ACO, Stockholm, Sweden) with ascorbic acid (a.0 mg/ml) added to prevent oxidation, dissolved in isotonic saline, at a rate of 0.05 ~tg. kg-1; adrenaline combined with the nonselective fl-adrenergic antagonist propranolol (Inderal, ICI, Manchester, UK) given as a 5-mg bolus dose intravenously followed by a constant infusion of 80 I-tg/min; and adrenaline combined with the relatively flvselective antagonist metoprolol (Seloken, Hassle, Gothenburg, Sweden) given at the same dose as propranolol. Rates of glucose appearance (Ra) and disposal (Rd) were determined by infusing D-(3-3H)-glucose (New England Nuclear, Boston, Mass, USA) dissolved in isotonic saline. A primed infusion of 15 ~tCi was given followed by a constant infusion of 10 ~tCi/h.
Euglycaemic clamp
The euglycaemic clamp was performed simultaneously with the measurements of glucose production and utilization. The clamps were performed after an overnight fast essentially according to De Fronzo et al. [15] as previously reported in detail [I 6] .
Following constant infusion of D-(3-3H)-glucose for 120 rain to achieve isotopic equilibration, the insulin infusion was started with a primed infusion for 10min followed by a constant infusion of 40 mU. (m 2)-1. min-~ for 120 min. The insulin infusion rate was then increased to 1200mU.(m 2) 1.min-1 for another 120min. Arterialized venous blood (O2 saturation 88%) was used to measure the blood glucose concentration every 90 s with an automatically operating glucose sensor (Gambro AB, Lund, Sweden) using the glucose oxidase technique. The rate of glucose infusion was adjusted to maintain the glucose concentration at euglycaemia (4.5 mmol/1).
Each subject was studied four times with at least 3 weeks between each study. The studies were performed in a randomized order with the infusion of either isotonic saline alone (placebo), adrenaline, adrenaline plus propranolol or adrenaline plus metoprolol during the euglycaemic clamp period with two insulin infusion rates.
Analytical procedures
During the isotopic equilibration period of 120 min blood samples for the determination of blood glucose and specific activity were taken before (at zero time), after 90 min and henceforth every 10 min, including the clamp periods. Blood glucose was determined with the glucose oxidase technique. Blood samples for the determination of specific activity of glucose, concentrations of free insulin, catecholamines, free fatty acids, propranolol and metoprolol were kept on ice and stored at -20 °C until analyzed. Measurements of the specific activity of glucose were performed on deproteinized plasma. The samples were counted in a liquid scintillation counter for 50 rain.
Samples for the determination of free insulin, catecholamines and free fatty acid levels were collected three times during the second hour of each clamp period, and samples for the determination of the propranolol and metoprolol concentrations were taken twice during the same time periods.
The free insulin levels were determined on the supernatant of polyethyleneglycol treated samples [17] with a radioimmunoassay technique using Phadeseph insulin-kit (Pharmacia, Uppsala, Sweden).
Free fatty acids were determined according to Trout et al. [18] and catecholamines by a liquid chromotographic method with electrochemical detection [19] .
The levels of propranolol and metoprolol were determined with a gaschromatographic method [20] .
Calculations
Under the experimental conditions used, the total glucose turnover for a given period of time could be calculated by adding the mean rate of the calculated endogenous glucose production during that period to the amount of glucose infused during the same period. As glucose utilization reached steady-state during the second hour of each clamp period (180-240 and 300-360 min), the glucose uptake during this period was used in the calculations. As the endogenous glucose production was completely inhibited during the high insulin infusion rate rate (1200 mU.(m 2) 2. min-1), the total glucose disposal during this period is equal to the mean glucose infusion rate during the same period. The reported levels of free insulin, free fatty acids and catecholamines during the clamp are the mean values during the second hour of each clamp period (180-240 and 300-360 min). The rates of glucose production (Ra) and glucose utilization (Rd) were determined by the method of primed constant tracer infusion [21] . This method assumes that rapid changes in the specific activity and concentration of glucose do not occur uniformly within the entire glucose pool. To compensate for non-uniform mixing, the non-steady state term of the equation was multiplied by a correction factor (pool-fraction) of 0.65 [22, 23] . A sliding fit technique employing three consecutive values of glucose concentration and specific activity was used in the calculation [241.
Statistical analyses
Data are shown as means + SEM. Statistical differences between the groups were calculated with analysis of variance.
Results
Catecholamine levels
The basal adrenaline levels were similar before the infusions (placebo 0.14 ___ 0.02; adrenaline 0.20 + 0.04; adrenaline + propranolol 0.15 + 0.02; adrenaline + met-oprolol 0.20 _+ 0.06 nmol/1). There was no significant increase in the adrenaline levels during the glucose damps combined with saline infusion at either insulin infusion rate (Table2). The adrenaline infusion produced high but physiological plasma levels, and steadystate was reached during both insulin infusion rates (3.30_+ 0.26 and 3.72 + 0.27 nmol/t respectively). When the adrenaline infusion was combined with propranolol, significantly higher levels were seen during the clamp with the low insulin infusion rate (6.08 +0.43 nmol/1; p < 0.001). However, this effect of propranolol was not seen in the presence of high insulin levels (Table2). The combined infusion of adrenaline and metoprolol produced adrenaline levels which were higher than adrenaline infusion alone but lower than adrenaline + propranolol.
The noradrenaline levels were similar before the infusions (placebo 0.74+0.13; adrenaline 0.72+0.11; adrenaline + propranolol 0.74 _+ 0.05 ; adrenaline + met- oprolol 0.73 ± 0.08 nmol/l). During placebo infusion there was no increase in noradrenaline levels during the euglycaemic clamps at either infusion rate (Table 2 ). Infusion of adrenaline, however, caused a significant elevation of the noradrenaline levels at both insulin infusion rates (0.95 + 0.12 and 0.99 + 0.15 nmol/1 respectively; p < 0.02). This effect was completely prevented by propranolol, when the noradrenaline levels were actually lower than during saline infusion (0.57 _+ 0.05 nmol/1; p<0.02). The noradrenaline levels remained unchanged when the adrenaline infusion was combined with metoprolol (Table 2) .
Propranolol and metoprolol levels
The propranolol and metoprolol concentrations were similar and tended to increase during the clamp with the high insulin infusion rate ( Table 2) .
Glucose levels
The glucose concentration during the clamps was similar in all studies: placebo 4.5 + 0. 
Insulin levels
The fasting levels of free insulin were similar before each study: placebo 4 _+ 0.3 ; adrenaline 4_+ 0.5; adrenaline + propranolol 4 + 0.5; adrenaline + metoprolol 12.
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38 E 3_+0mU/1. During the second hour of euglycaemic clamp with the low insulin infusion rate (40mU. (m2) -1 .min-1), steady-state levels of free insulin had been reached in all studies. Slightly higher insulin levels were seen during the adrenaline + propranolol infusion as compared to placebo (p < 0.05), whereas no difference was found between placebo and the other infusions (placebo 51 _+ 3 ; adrenaline 47 + 3; adrenaline + propranolol 64_+ 6; adrenaline + metoprolol 48 + 4 mU/1). Infusion of insulin at a 30 times higher rate (1200mU (m2)-l-min -1) resulted in free insulin levels that were about 150 times higher ( Table 2 ). The free insulin levels increased during the second hour of the clamp with the high insulin infusion rate (mean increase 21%) in all studies. There were, however, no significant differences between the groups (placebo 7421 _+ 447; adrenaline 7560 + 580; adrenaline + propranolol 7763 +_ 670; adrenaline + metoprolol 6913 ___ 709 mU/1).
Steady state glucose infusion rate
During the second hour of the low insulin clamp, the steady state glucose infusion rate was significantly (p < 0.001) lower during adrenaline infusion as compared to placebo (Table 2 ). This effect of adrenaline was completely reversed by propranolol but not by metoprolol ( Table 2) . A similar but less pronounced inhibitory effect of adrenaline was seen during the high insulin clamp (p < 0.01). This effect was also completely overcome by propranolol but not by metoprolol ( Table 2 ). The insulin-antagonistic effect of adrenaline was maintained unchanged throughout the 2 h clamp at each insulin concentration as evaluated by the steady state glucose infusion rates (reduction of glucose infusion rate by adrenaline compared to placebo with insulin 40mU-(m2)-l.min-l: 0-60min 68_+6; 60-120min 78 + 5%; with insulin 1200 mU. (m2) -I. min -1 0-60 rain 42 + 3, 60-120 min 37 ___ 5%, p > 0.10).
Glucose production
Under steady-state conditions, glucose production (Ra) is equal to glucose utilization (Rd), and no difference was found between the groups before the infusions were started (placebo 2.53_+0.17; adrenaline 2.20+ 0.12; adrenaline + propranolol 2.35_+ 0.18; adrenaline + metoprolol 2.12_+ 0.09 mg. kg -t. min-l).
Infusion of insulin completely inhibited the endogenous glucose production in the placebo group. This was the case even for the low insulin infusion rate (Fig. 1,  Table 2 ). In the presence of adrenaline, however, the same level of insulin only partly suppressed the glucose production (1.55 + 0.10 mg-kg -1. min-l). Propranolol, but not metoprolol, was able to completely overcome the effect of adrenaline on glucose production at the low insulin infusion rate (Fig. 1) .
The high insulin infusion rate completely inhibited glucose production also in the presence of adrenaline (Table 2 ). In fact, the calculated Ra values were negative at these high insulin levels and there was no significant difference between the groups (Table 2) .
Glucose util&ation
In the absence of adrenaline, glucose utilization increased about 3 times during the low insulin infusion rate (from 2.53+0.17 to 7.28_0.88mg.kg-l.min -1) (Fig.2) . A further 150-fold increase of the insulin levels only doubled the glucose utilization (to 14.68+ 1.14 mg-kg -1. min-1). Adrenaline caused a marked inhibition of the glucose utilization both at the low (78% inhibition) and at the high (37% inhibition) insulin levels (Fig. 2) . Infusion of propranolol prevented the inhibitory effect of adrenaline and this was particularly evident at the low insulin level (Table 2) . Metoprolol, on the other hand, did not prevent the inhibitory effect of adrenaline on glucose utilization at the low insulin infusion rate but appeared more effective at high insulin levels (Fig. 2) .
Thus, adrenaline markedly antagonized the effect of insulin on glucose utilization even in the presence of very high insulin concentrations. Propranolol, but not metoprolol, reversed the effect of adrenaline. To further analyse the effects, the individual glucose disposal rates were expressed as percent of the maximal rate for that that individual (=100%). When the glucose disposal rates are expressed in this way, the responsiveness to in-413 sulin alone (placebo) and to adrenaline + propranolol is almost identical while the curves for both adrenaline and adrenaline + metoprolol are markedly shifted to the right (Fig. 3) . From these data, the insulin concentration producing half-maximal effect on glucose disposal could be roughly estimated to about 40 mU/1 for both placebo and adrenaline+propranolol and to about 200 mU/1 for adrenaline and adrenaline + metoprolol.
Free fatty acids
The free fatty acid levels were similar before the infusions (placebo 718 +_ 98; adrenaline 832 + 77; adrenaline + propranolol 759 + 139; adrenaline + metoprolol 787_+131 p~mol/l). The levels also decreased with increasing insulin concentrations when adrenaline was infused alone or together with propranolol or metoprolol (Fig. 4 and Table 2 ).
Heart rates
The heart rates were similar before the infusions. An increase was seen in all subjects during the insulin and placebo infusion (from 64__+ 2 to 79 + 3 beats/rain during the high insulin infusion rate; p <0.002), even though the glucose levels were unchanged. The heart rates increased even further when adrenaline was infused during the clamps (from 65 + 5 to 94 + 5 beats/ min). This increase was prevented by the concomitant infusions of metoprolol or propranolol. In fact, in the presence of adrenaline+propranolol the heart rates were significantly lower than during placebo (from 62 + 3 to 53 + 4 beats/min; p < 0.001).
Discussion
The present study clearly shows that infusion of adrenaline to high physiological blood levels markedly antagonizes the effect of insulin on glucose turnover. This effect is exerted through the stimulation of fl2-adrenergic receptors.
The adrenaline levels were higher when the catecholamine infusion was combined with propranolol, which is in agreement with previous results [25] [26] [27] . Higher levels were also seen in the presence of metoprolol, showing the importance of both ill-and fl2-adrenergic receptors for the clearance of adrenaline.
The noradrenaline levels decreased during the combined infusion of adrenaline and propranolol, probably due to a preponderant a2-receptor stimulation which leads to an inhibition of noradrenaline release [28] . Conversely, the higher noradrenaline levels seen with adrenaline alone are probably due to the stimulation of presynaptic facilitating fl2-receptors [28] .
The insulin-antagonistic effect of adrenaline appears to be more pronounced for glucose utilization than for glucose production. This is supported by two observations. Firstly, the ability of adrenaline to stimulate the basal (preclamp) hepatic glucose production was prevented by the low insulin level while a marked inhibitory effect was seen on glucose disposal. Secondly, the inhibitory effect of adrenaline on glucose utilization remained even at very high insulin concentrations in contrast to the effect of adrenaline on glucose production. The physiological significance of this is, however, conjectural.
The complete inhibition of glucose production by a low insulin level (51 mU/1) in the absence of adrenaline is in agreement with the concept that hepatic glucose production is considerably more sensitive to insulin than glucose utilization [29, 30] . The same insulin concentration only produced a half-maximal increase in glucose disposal.
The effect of catecholamines on glucose production in man has been suggested to be mediated by both aand fl-adrenoceptor stimulation [25, 26, 31] . The c¢-adrenergic effect seems to partially mediated through the inhibition of insulin release [25] . The present results show that r-antagonists alone can completely inhibit the direct effect of adrenaline on glucose production when insulin is held constant. This effect, then, appears to be mediated solely by/q-receptor stimulation, which is in agreement with other recent suggestions [9, 32] . In addition, the finding that the relatively ill-selective drug, metoprolol, does not antagonize the effect of adrenaline shows the importance of fl2-receptors for catecholamine-stimulated glucose production in normal man. Under the current experimental conditions with euglycaemia and constant insulin levels, no evidence of a transient effect of adrenaline on glucose turnover was seen.
The half-maximal effect of insulin on glucose disposal was about 40 mU/1, which is in agreement with another study in healthy subjects [29] . Under normal conditions a maximal effect of insulin is reached at about 700 mU/1 [29] . Thus, the levels produced in the present study with the high insulin infusion rate ( ~7500 mU/1) should clearly exert a maximal effect on glucose utilization. Infusion of adrenaline at a rate sufficient to produce blood levels similar to those seen under normal stress situations, such as moderate hypoglycaemia [8] , caused a marked impairment of the insulin-stimulated glucose uptake both at physiological and supraphysiological plasma insulin levels. Thus, it seems that both insulin sensitivity and responsiveness are decreased in the presence of elevated adrenaline levels. The insulin-antagonistic effect of adrenaline at low insulin levels also seems to be preferentially mediated through the fl2-adrenoceptors, since it was prevented by simultaneous infusion of propranolol but not by metoprolol. Metoprolol was able to partly overcome the antagonistic effect of adrenaline at high insulin levels. The reason for this discrepancy is unclear. However, it seems unlikely that different fl-adrenoceptors should mediate the antagonistic effect of adrenaline at high and low insulin levels.
The r-antagonists propranolol and metoprolol are quipotent in reducing exercise-induced tachycardia, which is mainly a ill-mediated effect, when given intravenously [33] . Similar plasma concentrations of the antagonists were also seen in the present study supporting the concept that an equal degree of ill-blockade was reached.
The finding that mainly fl2-receptors mediate the antagonistic effect of catecholamines on insulin-stimulated glucose disposal provides an important explanation for the impairment in glucose recovery from hypoglycaemia seen with non-selective (ill + f12) but not ill-selective antagonists. We and others have previously reported that propranolol, but not metoprolol, impairs the recovery from hypoglycaemia in Type 1 diabetic patients [34] [35] [36] . Furthermore, propranolol has been reported to induce hypoglycaemia during prolonged physical exercise [37, 38] . This effect is probably also due to an impairment of the normal compensatory reduction of the peripheral glucose uptake [38] .
The insulin-antagonistic effect of the catecholamine infusion, shown by both a shift in the dose-response curve and a reduced responsiveness, is identical to the insulin-antagonistic effects produced by catecholamines on fat cells in vitro. We and others [12] [13] [14] have recently shown that incubation with catecholamines leads to a rapid reduction in insulin binding via a fl-adrenergic-dependent mechanism. The physiological importance of this finding is underlined by the recent observation that insulin binding to fat cells from patients with a phaeochromocytoma shows a negative correlation with the urinary catecholamine excretion [13] . Furthermore, catecholamines markedly inhibit the insulinstimulated glucose transport in rat fat cells provided that the ambient medium adenosine is degraded [10, 11] . This effect seems, in part, to be due to an inhibition of the insulin-induced translocation of the glucose transporters from the intracellular pool to the plasma membrane as well as to a reduction of the inherent activity of the glucose transporters [10] . The cellular sensitivity to insulin is also markedly reduced since about 5-10 fold higher insulin concentrations are required for a halfmaximal response.
Elevated levels of free fatty acids reduce glucose uptake in peripheral tissues during moderate hyperinsulinaemia [39] . Thus, one potentially contributing factor to the insulin-antagonistic effect of adrenaline on glucose utilization could be a simultaneous elevation of the free fatty acids due to an increased lipolysis [40, 41] . As, however, the free fatty acids decreased during the clamp periods in all experiments, this explanation seems unlikely.
Increasing the insulin infusion rate 30-fold (from 40 to 1200mU.kg -1 .min -1) caused about a 150-fold increase in the free insulin levels. A lower insulin clearance during high infusion rates has also been found in other studies [42, 43] and is probably due to saturation of the insulin removal system. The increased heart rate during iLhe insulin infusion in the absence of a decreased glucose level may be due to a direct chronotropic effect of insulin [44, 45] or may be the result of the increased release of noradrenaline [46] . Since the noradrenaline levels were somewhat increased during the insulin infusion, our findings favour the latter hypothesis. The haemodynamic effects seen during the infusion of adrenaline with either r-blocking agent were the expected and similar to those recorded with the respective drug in connection with hypoglycaemia [34] .
In conclusion, the present study shows that catecholamines, through the flz-receptors, antagonize the effect of insulin on glucose production and disposal. The insulin-antagonistic effect of adrenaline on glucose production is overcome by high insulin concentrations, whereas the effect on glucose disposal persists. Thus, in the presence of insulin, catecholamines are important modulators of peripheral glucose uptake. This effect is, from a quantiative point of view, the most important for the insulin-antagonistic action.
